Premium
Monitoring and treatment disparities for youth on antipsychotics
Author(s) -
Fatica Jack
Publication year - 2020
Publication title -
the brown university child and adolescent behavior letter
Language(s) - English
Resource type - Journals
eISSN - 1556-7575
pISSN - 1058-1073
DOI - 10.1002/cbl.30480
Subject(s) - irritability , psychiatry , impulsivity , medical prescription , schizophrenia (object oriented programming) , aggression , food and drug administration , autism , psychotropic drug , psychology , medicine , psychological intervention , clinical psychology , drug , pharmacology , cognition
The need for effective interventions in the management of neuropsychiatric conditions in youths has led to increased use of psychotropic medications, particularly antipsychotics. Several are approved by the Food and Drug Administration (FDA) for administration in youths to treat schizophrenia, bipolar disorder, autism‐related irritability, and Tourette's disorder. However, by and large, these medications are used off‐label to target dysregulated conduct or emotional features such as aggression (48% of treated symptoms), irritability (19%), and impulsivity (11%). Only 5% of prescriptions are for FDA‐approved indications.